Compare BDTX & NPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDTX | NPT |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Specialty Chemicals |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.5M | 127.1M |
| IPO Year | 2020 | N/A |
| Metric | BDTX | NPT |
|---|---|---|
| Price | $2.55 | $5.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $10.40 | N/A |
| AVG Volume (30 Days) | 604.8K | ★ 1.1M |
| Earning Date | 03-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.45 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.20 | $3.14 |
| 52 Week High | $4.94 | $13.48 |
| Indicator | BDTX | NPT |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | N/A |
| Support Level | $2.42 | N/A |
| Resistance Level | $2.86 | N/A |
| Average True Range (ATR) | 0.12 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 89.74 | 0.00 |
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Texxon Holding Ltd provides technology-enabled supply chain management services to customers in the plastics and chemical industries in East China. The company operates through two segments: Supply Chain Trading and Plastic Manufacturing. Its services include procurement, logistics, payments, and fulfillment for Chinese SMEs, and all revenue is generated from operations within the People's Republic of China.